

LIST OF TABLES

Title of the table	Page No.
Table 2.1: TNM classification as per AJCC guidelines.....	20
Table 2.2: Classification for staging.....	21
Table 2.3: TLRs and associated PAMPs and DAMPs.....	36
Table 2.4: Role of TLRs in progression of various cancers.....	41
Table 2.5: List of agonists of TLRs used in cancer treatment.....	46
Table 2.6: List of antagonists of TLRs used in cancer treatment.....	48
Table 4.1: Sequences of primers used in the study.....	59
Table 4.2: Cycling conditions of qPCR.....	61
Table 5.1: IC ₅₀ and IC ₂₅ of IRAK-1 &-4 dual inhibitor on HEp-2 cell line.....	70
Table 5.2: IC ₅₀ , IC _{6.25} and IC _{3.125} values of the chemo-drugs on HEp-2 cell line.....	79
Table 5.3: Comparison of the IC ₅₀ values of chemo-drugs on parent and chemo-resistant HEp-2.....	82
Table 5.4.: Comparison of IC ₅₀ values of IRAK-1 &-4 dual inhibitor on parent and chemo-resistant HEp-2.....	85
Table 5.5: C _t values of <i>Bcl-2</i> and <i>Bcl-xL</i> mRNA in the chemo-resistant cell line with and without IRAK-1 &-4 dual inhibitor treatment.....	86
Table 5.6: Comparison of IC ₅₀ values of docetaxel alone and in combination with IRAK-1 &-4 dual inhibitor.....	96
Table 5.7: Comparison of IC ₅₀ values of cisplatin alone and in combination with IRAK-1 &-4 dual inhibitor.....	97
Table 5.8: Comparison of IC ₅₀ values of 5-FU alone and in combination with IRAK-1 &-4 dual inhibitor.....	98
Table 6.1: GEO data-based analysis of BST-2 expression in tumor vs normal samples of HNSCC.....	120
Table 6.2: Summary of pro-oncogenic features of parent and chemo-resistant HNSCC cells dependent on TLR signaling.....	124

Table 6.3: Summary of pro-oncogenic features upon exposure to combination of chemotherapy and IRAKs based TLR signaling inhibitor in parent and chemo-resistant HNSCC cells.....	126
---	-----